 Aimmune Therapeutics Inc NASDAQ:AIMT Investment analysts at Piper Sandler dropped their Q2 2020 earnings per share EPS estimates for Aimmune Therapeutics in a research note issued to investors on Monday, April 6th. Piper Sandler analyst C. Raymond now forecasts that the biotechnology company will post earnings per share of 1.04 for the quarter, down ... 